Iron deficiency with normal ferritin levels in restless legs syndrome

Department of Geriatric Medicine, Unit 4, Merlin Park Regional Hospital, Galway, Ireland.
Sleep Medicine (Impact Factor: 3.15). 06/2005; 6(3):281-2. DOI: 10.1016/j.sleep.2004.10.008
Source: PubMed


This report describes a patient with iron deficiency in bone marrow examination and iron-responsive restless legs syndrome (RLS), in whom serum ferritin levels were well above the conventional cutoff for considering iron deficiency. The predictive value of serum ferritin for iron deficiency in RLS depends on the cutoff employed, on the pre-test likelihood of iron deficiency and on coexisting inflammatory conditions. Bone marrow examination is helpful when ferritin levels are equivocal. (c) 2004 Elsevier B.V. All rights reserved.

Download full-text


Available from: Shaun T O'Keeffe, May 13, 2014
120 Reads
  • Source
    • "Since ferroportin is implicated in cellular iron excretion and elevated transferrin is a sign of intracellular depletion, these findings suggest the presence of a disrupted turnover of iron in RLS. In a patient with RLS and normal serum ferritin, a bone marrow biopsy was consistent with medullary iron depletion.29 In an attempt to explain the relation of iron stores and dopamine function in the central nervous system it has been proposed that low central iron stores could affect the function of tyrosine hydroxylase. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Restless legs syndrome and periodic limb movement disorder of sleep are now recognized as prevalent, distinct, yet overlapping disorders affecting all age groups. Although delineation of the mechanisms underlying these disorders continues to be the focus of very intense research efforts, it has become apparent that there is a prominent role for dopaminergic agents in the clinical management of these patients. Among the various dopaminergic drugs, ropinirole has undergone relatively intense and critical scrutiny, and appears to provide a safe and efficacious treatment option for patients with these two conditions. The more recent development of a controlled formulation for this drug is likely to yield additional benefits such as improved adherence and reduced fluctuations in daytime and nighttime symptoms. However, there is not enough evidence at this time to support such assumption.
    Therapeutics and Clinical Risk Management 04/2010; 6:173-82. · 1.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Summary form only given. The standard technique of deposition of thin films, having the silicide composition and structure, involves magnetron sputtering of a pure metal film onto the surface of a silicon substrate and then high-temperature annealing. Deposition of thin films by magnetron sputtering of compacted silicide powder targets is of limited use because of the high content of gaseous and light metallic impurities stipulated by standard powder metallurgy processes. Thin silicide films deposited by sputtering such targets have high electrical resistivity and comparatively low reproducibility. A more advantageous procedure is deposition of silicide films by magnetron sputtering cast silicide targets of the necessary chemical composition. However, the casting of silicide targets for commercial magnetron sputtering is a well-known metallurgical problem because solidified tungsten silicides are very brittle. It seems that the optimal solution of this problem, which enables one to produce cast silicide sputtering targets, is mosaic targets consisting of copper bases and small cast silicide ingots attached to the base by soldering or another procedure. In this study we present our experimental results on the thin tungsten silicide films deposited by magnetron sputtering of mosaic cast tungsten disilicide targets. The cast tungsten disilicide ingots have been produced from 5N-purity silicon and high-purity tungsten
    Materials for Advanced Metallization, 1997. MAM '97 Abstracts Booklet., European Workshop; 04/1997
  • Journal of Laboratory and Clinical Medicine 03/2006; 147(2):56-7. DOI:10.1016/j.lab.2005.08.012 · 2.80 Impact Factor
Show more